Get the Stockscreener App
5.50
5.34%
-0.31
After Hours:
5.50
Passage Bio Inc stock is traded at $5.50, with a volume of 40,128.
It is down -5.34% in the last 24 hours and up +5.36% over the past month.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
See More
Previous Close:
$5.81
Open:
$5.69
24h Volume:
40,128
Relative Volume:
0.54
Market Cap:
$17.64M
Revenue:
-
Net Income/Loss:
$-37.68M
P/E Ratio:
-0.4647
EPS:
-11.8364
Net Cash Flow:
$-30.65M
1W Performance:
+0.55%
1M Performance:
+5.36%
6M Performance:
-45.27%
1Y Performance:
+1,307%
1-Day Range:
$5.50
$5.785
1-Week Range:
$4.92
$5.9387
52-Week Range:
$0.3195
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.50 | 18.64M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-21-26 | Downgrade | TD Cowen | Buy → Hold |
| Apr-21-26 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-31-26 | Initiated | Oppenheimer | Outperform |
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Passage Bio (PASG) Slides 6.33% as Stock Approaches Key Support at $5.34SuperTrend - newsline.com
Thryv Holdings Faces Continued Pressure as Shares Slide to $3.72Dollar Neutral Pair - newsline.com
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGAAP Earnings Report - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentAnalyst Consensus Shift - newsline.com
Passage Bio Inc. (PASG) Edges Higher as Buyers Defend Key Support LevelCumulative Volume - The Legal Advocate
Delhi Airport Becomes First Indian Infrastructure Facility to Deploy 'Skycast' Aviation Weather Intelligence SystemGAAP Earnings Report - newsline.com
Unusual Machines (UMAC) Surges 57% as Momentum Builds Above Key SupportInstitutional Sentiment - The Legal Advocate
Passage Bio Ends Gemma Collaboration, Philadelphia Office Lease - Moomoo
Passage Bio Ends Key Collaborations and Office Lease - TipRanks
Passage Bioterminates research, collaboration and license agreement with Gemma Bio Therapeutics - marketscreener.com
Passage BIOTerminates Research, Collaboration And License Agreement With Gemma BIO Therapeutics - TradingView
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Share GainsOne-Time Gain Impact - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionUpward Estimate Revision - The Legal Advocate
PASG Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseEarnings Volatility Report - The Legal Advocate
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio Shareholders Approve Directors and Executive Pay - TipRanks
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
PASG Technical Analysis & Stock Price Forecast - Intellectia AI
Barnes & Noble Education Inc (BNED) Surges 6.36%: Key Levels to WatchWMA Signal - newsline.com
PASG Q1 2026 Earnings: Narrower-than-expected loss lifts sharesAnalyst Consensus Shift - thelegaladvocate.com
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentCEO Earnings Statement - The Legal Advocate
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational ProgressCrowd Sentiment Entry - Newser
Passage Bio Inc. (PASG) Holds Steady Near Support as Biotechnology Sector Faces HeadwindsBeta Neutral Pair - Newser
Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options - Stock Titan
Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options - Stock Titan
Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director Sandip Kapadia awarded 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director receives 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) awards 10,539 options to director at $5.08 - Stock Titan
Passage Bio Inc stock (US70267E1055): gene therapy developer back in focus after recent moves - AD HOC NEWS
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Passage Bio Inc stock (US70267E1055): gene therapy hopes meet analyst caution - AD HOC NEWS
Gene Therapy In CNS Disorder Therapeutics Market Size in the 7MM - openPR.com
Passage Bio stock (US70267E1055): Cuts 75% of workforce after FDA feedback - AD HOC NEWS
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
TradingKey - TradingKey
Indian Stock Market Rises: Sensex Gains 50 Points, Nifty 50 Holds Above 23,400Slow Growth Warning - newsline.com
Krabbe Disease Treatment Market to Reach USD 786.45 Million - openPR.com
TD Cowen Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
MSN Money - MSN
GM1 Gangliosidosis Treatment Market to Reach USD 626.86 Million - openPR.com
Passage BIO, Inc. 1Q 2026: Net loss $(7.6)M, EPS $(2.36) — 10-Q Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Passage Bio (NASDAQ: PASG) faces cash shortfall, cuts workforce 75% - Stock Titan
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):